-
-
-
-
-
-
-
Citizens Upgrades Ironwood Pharmaceuticals (IRWD) to Market Outperform
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) Reiterates Full-Year 2025 LINZESS U.S. Net Sales Guidance and Raises Adjusted EBITDA Guidance
-
-
-
-
-
-
-
Ironwood Pharma (IRWD) dropped from S&P 600
-
-
-
-
-
-
-
JMP Securities Reiterates Market Outperform Rating on Ironwood Pharmaceuticals (IRWD)
-
-
353,174 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

